Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
3 other identifiers
interventional
470
21 countries
157
Brief Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Sep 2025
Longer than P75 for phase_2
157 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2025
CompletedFirst Posted
Study publicly available on registry
August 6, 2025
CompletedStudy Start
First participant enrolled
September 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 26, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 18, 2033
April 15, 2026
April 1, 2026
3.3 years
August 5, 2025
April 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
Approximately 3 months
Phase 3: Progression-Free Survival (PFS)
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Up to 5 years
Phase 3: Overall Survival (OS)
Up to 5 years
Secondary Outcomes (14)
Phase 2: Objective Response (OR)
Up to 5 years
Phase 2: PFS
Up to 5 years
Phase 2: Duration of Response (DOR)
Up to 5 years
Phase 2: Time to Response (TTR)
Up to 5 years
Phase 2: OS
Up to 5 years
- +9 more secondary outcomes
Study Arms (5)
Arm A
EXPERIMENTALArm B
EXPERIMENTALArm C
ACTIVE COMPARATORArm D
EXPERIMENTALArm E
ACTIVE COMPARATORInterventions
Specified dose on specified days
Eligibility Criteria
You may qualify if:
- Participants must have histologically confirmed advanced urothelial carcinoma.
- Participants must be eligible to receive platinum-based chemotherapy.
- Participants must be Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy.
- Participants treated only in the peri-operative setting must have relapsed within 12 months of the last dose of the treatment.
- Participants must have ≥ 1 measurable lesion per RECIST v1.1.
- Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
You may not qualify if:
- Participants must not have platinum-based chemotherapy exposure within 12 months.
- Participants must not have received \>2 prior regimens irrespective of the setting.
- Participants must not have prior ADC therapy targeting EGFR or HER3.
- Participants must not have prior therapy with topoisomerase 1 inhibitor.
- Participants must not have active, untreated brain metastases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (160)
Local Institution - 0167
Gilbert, Arizona, 85234, United States
Local Institution - 0162
Fullerton, California, 92835, United States
Local Institution - 0252
Palo Alto, California, 94304, United States
Local Institution - 0163
Sacramento, California, 95816, United States
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento, California, 95817, United States
Local Institution - 0251
San Francisco, California, 94115, United States
Local Institution - 0254
Santa Rosa, California, 95403, United States
Local Institution - 0245
Dillon, Colorado, 80435, United States
Shaw Cancer Center
Edwards, Colorado, 81632, United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
Local Institution - 0247
Miami, Florida, 33176, United States
University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536, United States
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Local Institution - 0195
Boston, Massachusetts, 02215, United States
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Local Institution - 0248
Buffalo, New York, 14203, United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Fairview Hospital
Cleveland, Ohio, 44111, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Local Institution - 0161
Columbus, Ohio, 43210, United States
Cleveland Clinic - Hillcrest Hospital
Mayfield Heights, Ohio, 44124, United States
Local Institution - 0141
Portland, Oregon, 97239, United States
Local Institution - 0186
Nashville, Tennessee, 37203, United States
Local Institution - 0084
Nashville, Tennessee, 37232, United States
Local Institution - 0249
Abilene, Texas, 79606, United States
Local Institution - 0187
Austin, Texas, 78705, United States
Intermountain Medical Center
Murray, Utah, 84107, United States
Local Institution - 0253
St. George, Utah, 84790, United States
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
Local Institution - 0188
Norfolk, Virginia, 23502, United States
Local Institution - 0200
Seattle, Washington, 98101, United States
Local Institution - 0255
Seattle, Washington, 98109, United States
Local Institution - 0028
CABA, Buenos Aires, CP1280AEB, Argentina
Local Institution - 0023
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina
Local Institution - 0024
ABB, Buenos Aires F.D., C1199ABB, Argentina
Local Institution - 0026
Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina
Local Institution - 0025
Córdoba, 5000, Argentina
Local Institution - 0027
Mendoza, M5500AYB, Argentina
Macquarie University
Macquarie University, New South Wales, 2109, Australia
GenesisCare North Shore
St Leonards, New South Wales, 2065, Australia
Austin Health
Heidelberg, Victoria, 3084, Australia
Medizinische Universität Wien
Vienna, State of Vienna, 1090, Austria
Klinik Ottakring
Vienna, State of Vienna, 1160, Austria
Medizinische Universitaet Innsbruck
Innsbruck, Tyrol, 6020, Austria
ZAS Augustinus
Wilrijk, Antwerpen, 2610, Belgium
AZ Maria Middelares
Ghent, Oost-Vlaanderen, 9000, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, 9000, Belgium
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, 4000, Belgium
Local Institution - 0129
Salvador, Estado de Bahia, 41253-190, Brazil
Local Institution - 0121
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Local Institution - 0130
Rio de Janeiro, 22451-100, Brazil
Local Institution - 0124
São Paulo, 01452-000, Brazil
Local Institution - 0020
Edmonton, Alberta, T6G 1Z2, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
Local Institution - 0050
Beijing, Beijing Municipality, 100034, China
Local Institution - 0224
Beijing, Beijing Municipality, 100091, China
Local Institution - 0048
Fuzhou, Fujian, 350001, China
The First Affiliated Hospital Of Fujian Medical University
Fuzhou, Fujian, 350005, China
Local Institution - 0056
Xiamen, Fujian, 361003, China
Local Institution - 0051
Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
Zhujiang Hospital
Guangzhou, Guangdong, 510280, China
Local Institution - 0201
Wuhan, Hubei, 430030, China
Local Institution - 0059
Changsha, Hunan, 410013, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210000, China
Local Institution - 0046
Nanjing, Jiangsu, 210009, China
Local Institution - 0114
Nantong, Jiangsu, 226361, China
Local Institution - 0206
Nanchang, Jiangxi, 330006, China
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Local Institution - 0156
Qingdao, Shandong, 266003, China
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Local Institution - 0042
Shanghai, Shanghai Municipality, 200032, China
West China Hospital, Sichuan University
Chengdu, Sichuan, 610066, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Local Institution - 0227
Tianjin, Tianjin Municipality, 300070, China
Local Institution - 0157
Hangzhou, Zhejiang, 310022, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Local Institution - 0064
Zhengzhou, 450008, China
Local Institution - 0115
Brno, Brno-město, 656 53, Czechia
Local Institution - 0146
Hradec Králové, Hradec Králové, 500 05, Czechia
Local Institution - 0041
Prague, Praha 5, 150 06, Czechia
Centre Antoine-Lacassagne
Nice, Alpes-Maritimes, 06189, France
CHU Strasbourg-Hautepierre
Strasbourg, Alsace, 67098, France
CHU de Bordeaux Hop St ANDRE
Bordeaux, Aquitaine, 33075, France
Centre Leon Berard
Lyon Cedex08, Auvergne-Rhône-Alpes, 69373, France
Local Institution - 0258
Brest, Finistère, 29200, France
Hôpital Foch
Suresnes, Hauts-de-Seine, 92151, France
Local Institution - 0002
Saint-Herblain, Loire-Atlantique, 44805, France
Local Institution - 0005
Marseille, Provence-Alpes-Côte d'Azur Region, 13273, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
Clermont-Ferrand, Puy-de-Dôme, 63011, France
Local Institution - 0001
Villejuif, Val-de-Marne, 94800, France
Hôpital Européen Georges Pompidou
Paris, 75015, France
Groupe hospitalier Paris saint Joseph
Paris, Île-de-France Region, 75014, France
NCT
Heidelberg, Baden-Wurttemberg, 69120, Germany
Studienpraxis Urologie
Nürtingen, Baden-Wurttemberg, 72622, Germany
TUM Klinikum
Munich, Bavaria, 81675, Germany
Klinikum Nürnberg Nord
Nuremberg, Bavaria, 90419, Germany
Caritas-Krankenhaus St. Josef
Regensburg, Bavaria, 93053, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Schleswig-Holstein, 24105, Germany
Universitätsklinikum Jena
Jena, Thuringia, 07747, Germany
Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin
Berlin, 10117, Germany
Universitaetsklinikum Duesseldorf
Düsseldorf, 40225, Germany
Krankenhaus Nordwest GmbH
Frankfurt, 60488, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
Marienhospital Herne
Herne, 44625, Germany
Universitaetsklinikum Ulm
Ulm, 89081, Germany
Local Institution - 0238
Cork, T12 DC4A, Ireland
Tallaght University Hospital
Dublin, D24 NR0A, Ireland
Rabin Medical Center
Petah Tikva, Central District, 4941492, Israel
Local Institution - 0106
Ẕerifin, Central District, 70300, Israel
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001, Israel
Rambam Health Care Campus
Haifa, Northern District, 3109601, Israel
A.O.U.C. Policlinico di Bari
Bari, Apulia, 70124, Italy
Ospedale San Martino
Genoa, Liguria, 16132, Italy
Istituto Nazionale Tumori Regina Elena
Rome, Roma, 00144, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, 56126, Italy
Istituto Oncologico Veneto IRCCS
Castelfranco Veneto, Veneto, 31033, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
Ospedale San Raffaele
Milan, 20132, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, 80131, Italy
Azienda Ospedaliero Universitaria di Parma
Parma, 43126, Italy
Local Institution - 0183
Kawasaki, Kanagawa, 216-8511, Japan
Local Institution - 0171
Bunkyo-ku, Tokyo, 1138603, Japan
Local Institution - 0169
Koto-ku, Tokyo, 135-8550, Japan
Local Institution - 0179
Toyoma, Toyama, 930-0194, Japan
Local Institution - 0036
Breda, North Brabant, 4818 CK, Netherlands
Local Institution - 0033
Amsterdam, North Holland, 1066 CX, Netherlands
Local Institution - 0031
Leeuwarden, Provincie Friesland, 8934 AD, Netherlands
Akershus Universitetssykehus
Lørenskog, Akershus, 1478, Norway
Sykehuset i Vestfold
Tønsberg, Vestfold, 3103, Norway
Sykehuset Østfold Kalnes
Sarpsborg, Østfold fylke, 1714, Norway
Centrul de Oncologie "Sfântul Nectarie"
Craiova, Dolj, 200542, Romania
Institutul Oncologic Cluj
Cluj-Napoca, 400015, Romania
Institutul Regional de Oncologie
Iași, 700483, Romania
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], 08035, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [Cataluña], 08041, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, 28034, Spain
Local Institution - 0199
Valencia, Valenciana, Comunitat, 46009, Spain
Hospital Infanta Cristina
Badajoz, 06006, Spain
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
Hospital Clinico San Carlos
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario Virgen Del Rocio
Seville, 41013, Spain
Karolinska Universitetssjukhuset Solna
Solna, Stockholms Län [se-01], 171 64, Sweden
Sahlgrenska Universitetssjukhuset
Gothenburg, Västra Götalands Län [se-14], 413 45, Sweden
Local Institution - 0241
Malmo, 205 02, Sweden
Cantonal Hospital St.Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
Ospedale Regionale Bellinzona e Valli
Bellinzona, Canton Ticino, 6500, Switzerland
Kantonsspital Graubünden
Chur, 7000, Switzerland
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
Local Institution - 0243
Glasgow, Glasgow City, G12 0YN, United Kingdom
St Bartholomew's Hospital
London, London, City of, EC1A 7BE, United Kingdom
Royal Marsden Hospital (Sutton)
London, Sutton, SM2 5PT, United Kingdom
Local Institution - 0230
Sheffield, S10 2SJ, United Kingdom
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 5, 2025
First Posted
August 6, 2025
Study Start
September 30, 2025
Primary Completion (Estimated)
January 26, 2029
Study Completion (Estimated)
November 18, 2033
Last Updated
April 15, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html